EN DE

Seyitler Kimya Sanayi A.S. (SEYKM) Fair Value & Analysis

Healthcare · TR · Market cap 954M TRY

SK Seyitler Kimya Sanayi A.S. SEYKM · IS
Price4.77 TRY
Fair Value3.54 TRY
Upside-25.8%
Quality40/100
Mixed Growth
Thin margins · 3.2% net margin
Low debt · generates free cash flow
Trails peers (4/12)
Narrow moat 12/100
Watch Seyitler Kimya Sanayi A.S. for free, get notified when fair value or trend changes. Watch for free
Evidence: Medium Range 2.45 TRY – 4.63 TRY Share as image

Fair value as of: Aug 1, 2026

From 9 valuation models · updated today

Share price −0.6% over the past month.

What matters now

  • The price sits above even our optimistic bull case (4.63 TRY). The favourable scenario is already priced in.
  • Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • A fairly wide model range (2.45 TRY to 4.63 TRY) leaves room in how you read the outcome.

Price vs Fair Value (12 months)

7.63 TRY 4.30 TRY Fair Value 3.54 TRY Aug 2025 Jul 2026

12‑month range 4.30 TRY – 7.63 TRY · fair‑value band 2.45 TRY – 4.63 TRY · the 4.77 TRY price screens above the 3.54 TRY fair value. As of Aug 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Seyitler Kimya Sanayi A.S. (SEYKM) currently trades at 4.77 TRY, while our model-based Fair Value estimate is 3.54 TRY, implying the stock looks roughly 25.8% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Seyitler Kimya Sanayi A.S. generated revenue of 251M TRY at a net margin of 3.2%. Revenue grew 11.5% year over year. It earns a return on equity of 1.6%. Net debt stands at 18.7M TRY. Fundamentals as of Aug 1, 2026

Our scenario range runs from 2.45 TRY (bear case) to 4.63 TRY (bull case); at 4.77 TRY, the current price sits above that range. The share trades about 40% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -26%, SEYKM screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 251M TRY
Revenue growth (YoY) +11.5%
Net margin 3.2%
Return on equity 1.6%
Free cash flow 72.0M TRY FY2025
P/E ratio 159.0
More key figures
Operating margin -6.4%
EPS (TTM) 0.0300 TRY
EPS growth (YoY) -14.1%
Net debt 18.7M TRY FY2023

Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 40/100
Profitability 9
Quality Growth 60
Cashflow 95
Fin. Strength 77
Investment 28
Low Volatility 37
Momentum 30
52W Momentum 30
Net Issuance 40

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Seyitler Kimya Sanayi A.S. develops and sells medical adhesive tape products in Turkey, the Middle East, Africa, Europe, and the Americas. The company offers surgical tapes, injection series, wound care, skin closure strip and eye pads, first aid strips, dialysis sets, heat patches, compress and swab, ointments, hemostatic series, and silicone products.

Full company description

Seyitler Kimya Sanayi A.S. develops and sells medical adhesive tape products in Turkey, the Middle East, Africa, Europe, and the Americas. The company offers surgical tapes, injection series, wound care, skin closure strip and eye pads, first aid strips, dialysis sets, heat patches, compress and swab, ointments, hemostatic series, and silicone products. Seyitler Kimya Sanayi A.S. was incorporated in 1991 and is headquartered in Turgutlu, Turkey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Seyitler Kimya Sanayi A.S. reported revenue of 242M TRY in FY2025 versus 60.2M TRY in FY2021, a compound +41.6%/yr. Reported net income was −39.5M TRY in FY2025.

Revenue +41.6%/yr
FY21 60.2M TRY
FY22 111M TRY
FY23 283M TRY
FY24 300M TRY
FY25 242M TRY
Net income
FY21 24.3M TRY
FY22 71.4M TRY
FY23 −73.8M TRY
FY24 −115M TRY
FY25 −39.5M TRY

Is SEYKM fairly valued? → Check now

Share or link this analysis
📋 Free embed code + live data for your site

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Seyitler Kimya Sanayi A.S. Fair Value". https://www.fairvalue-calculator.com/stock/SEYKM

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 / 0
FUTURE 58 / 28
PAST 6 / 22
HEALTH 100 / 96
DIVIDEND 0 / 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG C$20.93 C$10.43 -50%
EssilorLuxottica Société anonyme ESLOF $192.00 $126.51 -34%
Medline Inc MDLN $33.61 $31.78 -5%
HOYA Corporation HOCPY $158.38 $101.00 -36%
Becton, Dickinson and Company BDX $140.71 $104.17 -26%
Alcon Inc 2U3 €57.16 €44.21 -23%
ResMed Inc RMD $193.57 $187.89 -3%
West Pharmaceutical Services, Inc WST $329.71 $137.28 -58%
Terumo Corporation TRUMF $14.62 $12.65 -13%
Straumann Holding SAUHY $12.68 $5.49 -57%

Compare Seyitler Kimya Sanayi A.S. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Seyitler Kimya Sanayi A.S. (SEYKM) overvalued or undervalued?
As of Aug 1, 2026, our model estimates a fair value of 3.54 TRY versus a price of 4.77 TRY, about −26% (overvalued).
What is the fair value of SEYKM?
Our model-based fair value for Seyitler Kimya Sanayi A.S. is 3.54 TRY (as of Aug 1, 2026), built from audited fundamentals. The current price is 4.77 TRY.
What is the quality score of SEYKM?
Seyitler Kimya Sanayi A.S. has a Quality Score of 40/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Seyitler Kimya Sanayi A.S. (SEYKM)?
Seyitler Kimya Sanayi A.S. reported trailing-twelve-month revenue of about 251M TRY (latest available figure, as of Aug 1, 2026).
What is the net profit margin of SEYKM?
The net profit margin of Seyitler Kimya Sanayi A.S. is about 3.2%, meaning it keeps roughly 3.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Seyitler Kimya Sanayi A.S. and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.